<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510172</url>
  </required_header>
  <id_info>
    <org_study_id>KA-20060086</org_study_id>
    <nct_id>NCT00510172</nct_id>
  </id_info>
  <brief_title>Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2</brief_title>
  <official_title>Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesised that intravenous infusion of PGI2 induced headache or migraine and cranial
      vasodilatation in migraineurs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <completion_date type="Anticipated">September 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache and accompanying symptoms. Blood flow velocity in the middle cerebral artery, diameter changes in superficial temporal artery and radial artery.</measure>
    <time_frame>14 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure, pulse</measure>
    <time_frame>100 min</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Headache</condition>
  <condition>Migraine</condition>
  <condition>Vasodilatation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostacyclin, PGI2</intervention_name>
    <description>10 ng/kg/min of epoprostenol (stable PGI2)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NaCL 0,9%</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  migraine without aura and healthy apart from that

          -  age 18-55 years

          -  50-100 kg

          -  Secure contraceptives

        Exclusion Criteria:

          -  Tension Type Headache more than 3 time a month

          -  Other primary headaches

          -  Medication prior to the study (closer than 4 times plasma halflife)

          -  Migraine or headache 5 days prior to study.

          -  Hypertension (systolic BP &gt;150 mmHg and/or diastolic BP &gt;100 mmHg).

          -  Hypotension (systolic BP &lt;90 mmHg and/or diastolic BP &lt;50 mmHg).

          -  Heart-vessel disease of any kind incl cerebrovascular disease.

          -  Anamnestic or clinical signs of psychiatric disease or abuse.

          -  Anamnestic or clinical signs of disease of any kind relevant for participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Troels Wienecke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Troels Wienecke, MD</last_name>
    <phone>+ 45 43 23 45 14</phone>
    <email>trowie01@glo.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Troels Wienecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2007</study_first_posted>
  <last_update_submitted>July 30, 2007</last_update_submitted>
  <last_update_submitted_qc>July 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2007</last_update_posted>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <keyword>Vasodilatation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

